SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group

Trial Profile

SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Saracatinib (Primary) ; Docetaxel; Prednisolone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SAPROCAN
  • Most Recent Events

    • 16 May 2016 Status changed from recruiting to completed.
    • 11 Dec 2015 Accrual to date is 89% according to the United Kingdom Clinical Research Network record.
    • 05 Nov 2015 Accrual to date is 87% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top